First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
After ZW171's exit, ZW251 enters the clinic.
Petosemtamab's phase 2 data in this setting should come by the year end.
The company is to test its KLK2-targeting pasritamig in a late-line setting.
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.